Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06745284 · ClinicalTrials.gov registry record · Phase 1

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

A Phase 1 study of Obesity, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
2
Study locations

NCT06745284 is a Phase 1 study of Obesity that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 60 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06745284, a Phase 1 study of Obesity, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy and breaks down fat. This study compares survodutide with another medicine called semaglutide. Survodutide is being developed to treat people with obesity. Semaglutide is already used to treat people with obesity. Participants are put into 2 groups by chance. One group gets survodutide and the other group gets semaglutide. Participants get survodutide or semaglutide as an injection under the skin once a week. Participants are in the study for 8-10 months depending on how long the treatment is given. During this time, they visit the study site weekly. Some of the visits may also be done at the participant's home instead of the study site. At some of the visits, doctors test how much energy a participant's body uses. This is done in a special room where they measure the oxygen that is breathed in and the carbon dioxide that is breathed out by the participant. The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions Studied

Obesity

Interventions

  • DRUG Semaglutide
  • DRUG Survodutide

Study Locations (2)

Florida

  • Translational Research Institute for Metabolism and Diabetes - Orlando

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-03-26
Est. Completion 2027-01-08
Phase Phase 1

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06745284

The ClinicalTrials.gov registry entry for NCT06745284 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide is the first listed.

NCT06745284 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT06745284 about?

NCT06745284 is a clinical study titled "A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity". This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy and breaks down fat. ...

What is the current status of trial NCT06745284?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-03-26. Estimated completion is 2027-01-08.

What conditions does trial NCT06745284 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06745284?

The interventions under investigation include: Semaglutide (DRUG), Survodutide (DRUG).

Who is sponsoring clinical trial NCT06745284?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06745284 being conducted?

This trial has 2 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.